Serum biomarkers for heart failure

Cardiovascular Pathology

Volumn 15, Issue 3, 2006, Pages 144-149

  Jarolim, Petr ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; ENDOTHELIN; UROTENSIN II;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE MARKER; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; LABORATORY TEST; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT;

AMINO ACID SEQUENCE; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; ENDOTHELINS; HEART FAILURE, CONGESTIVE; HUMANS; MOLECULAR SEQUENCE DATA; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; UROTENSINS;

EID: 33646340180     PISSN: 10548807     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carpath.2006.01.001     Document Type: Article

References (46)

1. Francis G., Goldsmith S., Levine T., Olivari M., and Cohn J. The neurohumoral axis in congestive heart failure. Ann Intern Med 101 (1984) 370-377
2. Yamamoto K., Burnett J., Jougasaki M., et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 28 (1996) 988-994
3. Davidson N., Naas A., Hanson J., Kennedy N., Coutie W., and Struthers A. Comparison of atrial natriuretic peptide B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Am J Cardiol 77 (1996) 828-831
4. Omland T., Aakvaag A., Bonarjee V., et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 93 (1996) 1963-1969
5. de Bold A., Borenstein H., Veress A., and Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 28 (1981) 89-94
6. Shimonaka M., Saheki T., Hagiwara H., et al. Purification of atrial natriuretic peptide receptor from bovine lung. Evidence for a disulfide-linked subunit structure. J Biol Chem 262 (1987) 5510-5514
7. Schenk D., Phelps M., Porter J., Fuller F., Cordell B., and Lewicki J. Purification and subunit composition of atrial natriuretic peptide receptor. Proc Natl Acad Sci U S A 84 (1987) 1521-1525
8. Sudoh T., Kangawa K., Minamino N., and Matsuo H. A new natriuretic peptide in porcine brain. Nature 332 (1988) 78-81
9. Mukoyama M., Nakao K., Hosoda K., et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 87 (1991) 1402-1412
10. Arimura J., Minamino N., Kangawa K., and Matsuo H. Isolation and identification of C-type natriuretic peptide in chicken brain. Biochem Biophys Res Commun 174 (1991) 142-148
11. Silver M., Maisel A., Yancy C., et al. BNP Consensus Panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail 10 (2004) 1-30
12. de Lemos J., McGuire D., and Drazner M. B-type natriuretic peptide in cardiovascular disease. Lancet 362 (2003) 316-322
13. Sabatine M., Morrow D., de Lemos J., et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol 44 (2004) 1988-1995
14. Maisel A. B-type natriuretic peptide measurements in diagnosing congestive heart failure in the dyspneic emergency department patient. Rev Cardiovasc Med 3 Suppl 4 (2002) S10-S17
15. Morrow D., de Lemos J., Blazing M., et al. Prognostic value of B-type natriuretic peptide during follow-up of patients with unstable coronary artery disease in the A to Z trial. JAMA 294 (2005) 2866-2871
16. Mega J., Morrow D., de Lemos J., et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol 44 (2004) 335-339
17. Wylie J., Murphy S., Morrow D., de Lemos J., Antman E., and Cannon C. Validated risk score predicts the development of congestive heart failure after presentation with unstable angina or non-ST-elevation myocardial infarction: results from OPUS-TIMI 16 and TACTICS-TIMI 18. Am Heart J 148 (2004) 173-180
18. Morrow D., de Lemos J., Sabatine M., et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 41 (2003) 1264-1272
19. Arakawa N., Nakamura M., Aoki H., and Hiramori K. Relationship between plasma level of brain natriuretic peptide and myocardial infarct size. Cardiology 85 (1994) 334-340
20. Talwar S., Squire I., Downie P., et al. Profile of plasma N-terminal proBNP following acute myocardial infarction; correlation with left ventricular systolic dysfunction. Eur Heart J 21 (2000) 1514-1521
21. Morita E., Yasue H., Yoshimura M., et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 88 (1993) 82-91
22. Motwani J., McAlpine H., Kennedy N., and Struthers A. Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction. Lancet 341 (1993) 1109-1113
23. Omland T., Lie R., Aakvaag A., Aarsland T., and Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 89 (1994) 1573-1579
24. Jernberg T., Lindahl B., Siegbahn A., et al. N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J Am Coll Cardiol 42 (2003) 1909-1916
25. Jernberg T., Stridsberg M., Venge P., and Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 40 (2002) 437-445
26. Morimoto T., Hayashino Y., Shimbo T., Izumi T., and Fukui T. Is B-type natriuretic peptide-guided heart failure management cost-effective?. Int J Cardiol 96 (2004) 177-181
27. Beck-da-Silva L., de Bold A., Fraser M., Williams K., and Haddad H. BNP-guided therapy not better than expert's clinical assessment for beta-blocker titration in patients with heart failure. Congest Heart Fail 11 (2005) 248-253
28. Mueller T., Gegenhuber A., Dieplinger B., Poelz W., and Haltmayer M. Capability of B-type natriuretic peptide (BNP) and amino-terminal proBNP as indicators of cardiac structural disease in asymptomatic patients with systemic arterial hypertension. Clin Chem 51 (2005) 2245-2251
29. Sinha A., Breithardt O., Schmid M., and Stellbrink C. Brain natriuretic peptide release in cardiac surgery patients. Thorac Cardiovasc Surg 53 (2005) 138-143
30. Daugaard G., Lassen U., Bie P., et al. Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail 7 (2005) 87-93
31. Halse K., Lindegaard M., Goetze J., Damm P., Mathiesen E., and Nielsen L. Increased plasma pro-B-type natriuretic Peptide in infants of women with type 1 diabetes. Clin Chem 51 (2005) 2296-2302
32. Zhou L., Giacherio D., Cooling L., and Davenport R. Use of B-natriuretic peptide as a diagnostic marker in the differential diagnosis of transfusion-associated circulatory overload. Transfusion 45 (2005) 1056-1063
33. Doust J., Glasziou P., Pietrzak E., and Dobson A. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med 164 (2004) 1978-1984
34. Wang C., FitzGerald J., Schulzer M., Mak E., and Ayas N. Does this dyspneic patient in the emergency department have congestive heart failure?. JAMA 294 (2005) 1944-1956
35. Chan J., Knudson O., Wu F., Morser J., Dole W., and Wu Q. Hypertension in mice lacking the proatrial natriuretic peptide convertase corin. Proc Natl Acad Sci U S A 102 (2005) 785-790
36. Forssmann W., Meyer M., and Forssmann K. The renal urodilatin system: clinical implications. Cardiovasc Res 51 (2001) 450-462
37. Cody R., Atlas S., Laragh J., et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest 78 (1986) 1362-1374
38. John S., Krege J., Oliver P., et al. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science 267 (1995) 679-681
39. John S., Veress A., Honrath U., et al. Blood pressure and fluid-electrolyte balance in mice with reduced or absent ANP. Am J Physiol 271 (1996) R109-R114
40. Bertinchant J., Combes N., Polge A., et al. Prognostic value of cardiac troponin T in patients with both acute and chronic stable congestive heart failure: comparison with atrial natriuretic peptide, brain natriuretic peptide and plasma norepinephrine. Clin Chim Acta 352 (2005) 143-153
41. Wei C., Lerman A., Rodeheffer R., et al. Endothelin in human congestive heart failure. Circulation 89 (1994) 1580-1586
42. Krum H., Goldsmith R., Wilshire-Clement M., Miller M., and Packer M. Role of endothelin in the exercise intolerance of chronic heart failure. Am J Cardiol 75 (1995) 1282-1283
43. Stangl K., Dschietzig T., Richter C., et al. Pulmonary release and coronary and peripheral consumption of big endothelin and endothelin-1 in severe heart failure: acute effects of vasodilator therapy. Circulation 102 (2000) 1132-1138
44. Pousset F., Isnard R., Lechat P., et al. Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J 18 (1997) 254-258
45. Pearson D., Shively J., Clark B., et al. Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci U S A 77 (1980) 5021-5024
46. Russell F. Emerging roles of urotensin-II in cardiovascular disease. Pharmacol Ther 103 (2004) 223-243